>>Description of the research protocol "NeoRHEA"

Neoadjuvant Biomarker Research Study of Palbociclib Combined with Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast Cancer
Phase II study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Cancer du sein Néo-adjuvant
Brugmann identifier : NeoRHEA
EudraCT identifier : 2016-000879-24


Involved department : Hemato-oncology
Principal investigator : Besse/Efira
Sponsor : IJB
Contact : Clinical Research Unit

>This protocol was approved by the Bordet ethics committee.